Clinuvel Pharmaceuticals Statistics

Total Valuation

Clinuvel Pharmaceuticals has a market cap or net worth of AUD 657.30 million. The enterprise value is 474.31 million.

Market Cap	657.30M
Enterprise Value	474.31M

Important Dates

The next estimated earnings date is Thursday, November 21, 2024.

Earnings Date	Nov 21, 2024
Ex-Dividend Date	Sep 5, 2024

Share Statistics

Clinuvel Pharmaceuticals has 49.95 million shares outstanding. The number of shares has decreased by -1.52% in one year.

Current Share Class	n/a
Shares Outstanding	49.95M
Shares Change (YoY)	-1.52%
Shares Change (QoQ)	-2.16%
Owned by Insiders (%)	10.40%
Owned by Institutions (%)	23.62%
Float	41.26M

Valuation Ratios

The trailing PE ratio is 18.85 and the forward PE ratio is 18.38. Clinuvel Pharmaceuticals's PEG ratio is 1.78.

PE Ratio	18.85
Forward PE	18.38
PS Ratio	7.44
PB Ratio	3.25
P/TBV Ratio	n/a
P/FCF Ratio	20.88
P/OCF Ratio	n/a
PEG Ratio	1.78

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.55, with an EV/FCF ratio of 15.07.

EV / Earnings	13.31
EV / Sales	5.38
EV / EBITDA	9.55
EV / EBIT	9.77
EV / FCF	15.07

Financial Position

The company has a current ratio of 8.81, with a Debt / Equity ratio of 0.00.

Current Ratio	8.81
Quick Ratio	8.33
Debt / Equity	0.00
Debt / EBITDA	0.02
Debt / FCF	0.03
Interest Coverage	10.90

Financial Efficiency

Return on equity (ROE) is 19.39% and return on invested capital (ROIC) is 16.43%.

Return on Equity (ROE)	19.39%
Return on Assets (ROA)	14.29%
Return on Capital (ROIC)	16.43%
Revenue Per Employee	5.51M
Profits Per Employee	2.23M
Employee Count	16
Asset Turnover	0.42
Inventory Turnover	0.77

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.56% in the last 52 weeks. The beta is 0.92, so Clinuvel Pharmaceuticals's price volatility has been similar to the market average.

Beta (5Y)	0.92
52-Week Price Change	-19.56%
50-Day Moving Average	13.97
200-Day Moving Average	14.61
Relative Strength Index (RSI)	35.29
Average Volume (20 Days)	87,792

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Clinuvel Pharmaceuticals had revenue of AUD 88.18 million and earned 35.64 million in profits. Earnings per share was 0.70.

Revenue	88.18M
Gross Profit	80.45M
Operating Income	48.57M
Pretax Income	50.68M
Net Income	35.64M
EBITDA	49.32M
EBIT	48.57M
Earnings Per Share (EPS)	0.70

Full Income Statement

Balance Sheet

The company has 183.87 million in cash and 879,784 in debt, giving a net cash position of 182.99 million or 3.66 per share.

Cash & Cash Equivalents	183.87M
Total Debt	879,784
Net Cash	182.99M
Net Cash Per Share	3.66
Equity (Book Value)	203.01M
Book Value Per Share	4.05
Working Capital	196.85M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 37.05 million and capital expenditures -5.58 million, giving a free cash flow of 31.48 million.

Operating Cash Flow	37.05M
Capital Expenditures	-5.58M
Free Cash Flow	31.48M
FCF Per Share	0.63

Full Cash Flow Statement

Margins

Gross margin is 91.23%, with operating and profit margins of 55.08% and 40.41%.

Gross Margin	91.23%
Operating Margin	55.08%
Pretax Margin	57.47%
Profit Margin	40.41%
EBITDA Margin	55.93%
EBIT Margin	55.08%
FCF Margin	35.70%

Dividends & Yields

This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.37%.

Dividend Per Share	0.05
Dividend Yield	0.37%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	6.93%
Buyback Yield	1.52%
Shareholder Yield	1.90%
Earnings Yield	5.30%
FCF Yield	4.79%

Dividend Details

Stock Splits

The last stock split was on November 12, 2010. It was a reverse split with a ratio of 0.1.

Last Split Date	Nov 12, 2010
Split Type	Reverse
Split Ratio	0.1

Scores

Clinuvel Pharmaceuticals has an Altman Z-Score of 19.42.

Altman Z-Score	19.42
Piotroski F-Score	n/a